The pathophysiology of cancer-induced bone pain: current understanding
- 1 June 2004
- journal article
- review article
- Published by SAGE Publications in Palliative Medicine
- Vol. 18 (4), 267-274
- https://doi.org/10.1191/0269216304pm887ra
Abstract
Cancer-induced bone pain (CIBP) is a common clinical problem. Although treatment has been revolutionised in the past 10 years with the introduction of bisphosphonates, pain arising spontaneously or from movement, remains a leading cause of unresolved pain in many patients. Until recently little was understood about the peripheral and central mechanisms of bone pain. Insight into the mechanisms of osteoblast and osteoclast activation, via receptor activator for nuclear factor kB (RANK) dependent and independent mechanisms and a re-evaluation of primary afferent terminals within bone have led to a suggestion that CIBP may be a mixture of inflammatory and neuropathic stimuli. The recently published animal model of localised but progressive bone destruction has allowed greater insight into the peripheral and dorsal horn pathophysiology, which hitherto was precluded. Immunocytochemical markers of neurotransmitters and receptors indicate that CIBP has unique characteristics, unlike neuropathy or inflammation. Evidence for an increased excitability within the dorsal horn, and especially Lamina I, and possible mechanisms underlying this unique pain state will be discussed.Keywords
This publication has 75 references indexed in Scilit:
- Superficial NK1-expressing neurons control spinal excitability through activation of descending pathwaysNature Neuroscience, 2002
- A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysisEuropean Journal Of Cancer, 2002
- Osteoprotegerin Abrogates Chronic Alcohol Ingestion-Induced Bone Loss in MiceJournal of Bone and Mineral Research, 2002
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- A prospective multicenter assessment of the Edmonton staging system for cancer painJournal of Pain and Symptom Management, 1995
- A Double‐Blind Study with Placebo Control of Intramuscular Ketorolac Tromethamine in the Treatment of Cancer PainThe Journal of Clinical Pharmacology, 1989
- Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissuesJournal of the Autonomic Nervous System, 1988
- Analgesic Efficacy of Ketoprofen in Postpartum, General Surgery, and Chronic Cancer PainThe Journal of Clinical Pharmacology, 1988
- A Double-Blind Parallel Evaluation of the Efficacy and Safety of a Single Dose of Ketoprofen in Cancer PainThe Journal of Clinical Pharmacology, 1988